Suzhou Yusen New Drug Development

Suzhou Yusen New Drug Development is a clinical-stage biopharmaceutical company headquartered in Suzhou, China, dedicated to the discovery and development of novel small molecule drugs. The company's primary research focus lies in the field of immunology and oncology, with a particular emphasis on the Janus kinase (JAK) signaling pathway. Its lead clinical candidate, YS-101, is a pan-JAK inhibitor being developed for various autoimmune conditions such as alopecia areata and rheumatoid arthritis. Yusen Pharma aims to address significant unmet medical needs by creating highly effective and safe therapeutic options through advanced medicinal chemistry. The company operates out of the Suzhou Industrial Park, benefiting from the region's robust biotechnology ecosystem.